Close Menu

personalized medicine

Evotec will access Indivumed's IndivuType multi-omics cancer database to discover and develop new precision therapeutics for colorectal cancer.

The NGS assay is designed to help physicians to identify non-small cell lung cancer patients who may benefit from eight targeted therapies.

The company believes that helping to funnel patients to the trial will help support its own goals to gather genomic information on targeted cancer therapy efficacy.

In a small study, melanoma patients with BRAF V600K mutations responded better to immunotherapy while those with V600E mutations had a better response to targeted therapy.

After raising $320M in venture capital, Tempus hopes to sequence 100,000 samples in 2019 as it expands its precision medicine program into depression and diabetes.

In order to be eligible for the drug, patients must have NTRK fusions, which may be determined via various tests including NGS and FISH.

The program, which includes OncoDNA, will evaluate the use of molecular diagnostic testing in personalizing treatments for cancer patients in Luxembourg.

The study is testing the efficacy of cancer treatments that are selected based on genomic markers driving patients' tumors, regardless of cancer type.

The NCI will launch a lab network to provide researchers with centralized assays for conducting genomic and pharmacodynamic analysis for molecularly targeted drugs.

Though it's still struggling with data integration, Detroit's Henry Ford Health System is standardizing workflows and beginning to measure outcomes.

Pages